Bystolic (nebivolol) / Menarini, AbbVie - LARVOL DELTA

FDA-approved drug library screen identifies antidepressants, antimicrobials, anti-COPD, and anti-CVD agents as blockers of NLRP3 inflammasome and sepsis in a sex-dependent manner. (PubMed, bioRxiv) - "Various classes of drugs, such as antidepressants (Fluoxetine, Duloxetine), antihypertensives (Irbesartan, amlodipine, nebivolol), antidiabetics (Rosiglitazone), β-adrenergic agonists (Salmeterol), antimalarials (Mefloquine), antifungals (Azoles, ciclopirox), and antivirals (Saquinavir, Remdesivir), were identified as potent blockers of either priming or assembly of NLRP3 inflammasome. Mice treated with LPS-priming blockers showed a sex-specific increase in survival rate in the mouse model of LPS-induced mortality, validating the in vitro screen. Further studies in primary human cells and in vivo disease models are needed to assess the repurposing and therapeutic relevance of identified drugs."

FDA event • Journal • Alzheimer's Disease • Asthma • Chronic Obstructive Pulmonary Disease • CNS Disorders • Diabetes • Genetic Disorders • Gout • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Movement Disorders • Novel Coronavirus Disease • Obesity • Parkinson's Disease • Pulmonary Disease • Respiratory Diseases • Rheumatology • Septic Shock • NLRP3

The Common Beta Blocker: A Cause of Non-Melanoma and Melanoma Skin Cancer? (AAD 2026) - " We conducted a retrospective cohort study using the TriNetX Research Network, including AF patients prescribed carvedilol, metoprolol, atenolol, bisoprolol, or nebivolol. Beta-blocker use does not appear broadly associated with cutaneous malignancy risk in AF patients; however, metoprolol may uniquely influence BCC and SCC risk. Further prospective studies are warranted to clarify agent-specific dermatologic safety profiles."

Atrial Fibrillation • Basal Cell Carcinoma • Genetic Disorders • Melanoma • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

IMPACT OF NEBIVOLOL VERSUS CARVEDILOL ON LONG-TERM CLINICAL OUTCOMES IN ST ELEVATION MYOCARDIAL INFARCTION PATIENTS WITH DIABETES MELLITUS TREATED WITH DRUG-ELUTING STENTS (ACC 2026) - "In STEMI patients with DM treated with DESs, Nebivolol and Carvedilol showed similar clinical outcomes for all-cause death and MACE up to 3 years."

Clinical • Clinical data • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction

DOES NEBIVOLOL FIT IN THE HEART FAILURE WITH PRESERVED/MIDRANGE EJECTION FRACTION TREATMENT ALGORITHM? INSIGHTS FROM NETWORK META-ANALYSIS (ACC 2026) - "A PRISMA-based search identified six trials involving Nebivolol, Bisoprolol, Atenolol, Carvedilol, and placebo. Nebivolol demonstrates a favorable efficacy profile in improving symptoms, function, and potentially reducing events in HFpEF/HFmrEF. These findings suggest that when β-blockade is indicated, Nebivolol may be the preferred choice. Further large-scale, phenotype-stratified trials are needed to define the role of Nebivolol in HFpEF management."

Retrospective data • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertension

Plaque Morphology-Dependent Regression of Tandem Coronary Plaques Under Intensive Lipid-Lowering Therapy. (PubMed, Catheter Cardiovasc Interv) - "Although PCI was considered, in accordance with the patient's preference and guideline recommendations, medical therapy with high-intensity statin, ezetimibe, aspirin, nebivolol, and isosorbide dinitrate was initiated. The patient remained asymptomatic with preserved exercise capacity. This case suggests that plaque morphology may influence the response to lipid-lowering therapy and highlights the value of multimodality imaging with lesion-specific physiological assessment in individualized management of stable coronary disease."

Journal • Cardiovascular

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Not yet recruiting | Sponsor: Policlinico San Donato S.p.A.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Nebivolol-induced bi-directional modulation of intracellular kinases contributes to the inhibition of triple-negative breast cancer. (PubMed, Biochem Pharmacol) - "These findings demonstrate that nebivolol exerts anti-tumor effects on TNBC via deliberate modulation of intracellular signaling pathways in the tumor cells. This study promotes the potential of repurposing β-blockers as anti-cancer therapeutics and highlights the clinical promise of combining them with selective kinase inhibitors."

Journal • Breast Cancer • Metabolic Disorders • Oncology • Solid Tumor • Triple Negative Breast Cancer

IDENTIFYING MEANINGFUL PATIENT SAVINGS ON GENERICS: DIRECT-TO-CONSUMER PRICES VS COMMERCIAL INSURANCE (ISPOR 2026) - "DTC pharmacies such as MCCPDC meaningfully lower out-of-pocket costs for higher-cost generic prescriptions which could otherwise be difficult to afford. Commercially insured patients should consider DTC pharmacies when their copayment or coinsurance for a generic medication exceeds $15, and particularly when it exceeds $100."

Clinical • Reimbursement • US reimbursement • CNS Disorders • Depression • Endocrine Disorders • Erectile Dysfunction • Multiple Sclerosis

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - P4 | N=2400 | Recruiting | Sponsor: Martin Huelsmann

New P4 trial • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - P4 | N=2400 | Recruiting | Sponsor: Martin Huelsmann | Unknown status ➔ Recruiting | Trial completion date: Feb 2021 ➔ Dec 2026 | Trial primary completion date: Feb 2019 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Exploring lactoferrin as an innovative covalently immobilized chiral selector for the selective separation of pharmaceutical enantiomers using HPLC. (PubMed, Anal Chim Acta) - "HPLC remains the primary choice for all pharmaceutical research, as it offers higher sensitivity, reliability, and reproducibility. This work introduces LF as a novel, multifunctional CS for HPLC, covalently immobilized for the first time, expanding the toolbox of protein-based chiral stationary phases. Moreover, the study also offers a critical insight into the limitations of relying solely on computational predictions, empirically demonstrating that solvent effects can override binding affinities, a phenomenon not captured by standard docking simulations."

Journal

The Effects of Nebivolol on Moderate Traumatic Brain Injury in a Rat Model: Implications for Pediatric Neuroprotection. (PubMed, Iran J Child Neurol) - "Nebivolol reduces inflammation, stabilizes cardiovascular function, and finally promotes cognitive rehab. The pleiotropic profile of Nebivolol promises reliable research in pediatric-focused models and forthcoming clinical trials."

Journal • Preclinical • Cardiovascular • CNS Disorders • Inflammation • Pediatrics • Vascular Neurology

Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients (clinicaltrials.gov) - P4 | N=40 | Completed | Sponsor: Kafrelsheikh University

New P4 trial • Cardiovascular • Fibrosis • Gastroenterology • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Pulmonary Arterial Hypertension

Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy. (PubMed, PLoS One) - "This in silico study predicts Carteolol as a potential dual-targeting therapeutic agent, requiring biochemical and cellular validation before clinical relevance can be established."

Journal • Colorectal Cancer • Oncology • Solid Tumor • EGFR • KRAS

Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study. (PubMed, J Am Heart Assoc) - "In this retrospective cohort study of patients with hypertension without heart failure, nebivolol was associated with greater reductions in blood pressure and heart rate, as well as a lower risk of all-cause mortality and major adverse cardiovascular events, compared with carvedilol and other beta blockers. Although these findings suggest potential benefits of nebivolol in this population, prospective studies are needed to validate these observations."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Potentiating anti-inflammatory and antioxidant effects in vitro: the combined action of zofenoprilat and nebivolol. (PubMed, Pharmacol Rep) - "This combination therapy, by addressing multiple pathogenic pathways simultaneously, could potentially be beneficial in patients with cardiovascular risk conditions. In conclusion, the combination of ZOFE and NEBI offers a potentially promising therapeutic approach for managing hypertension and protecting vascular health, aiming at improving clinical outcomes for patients with cardiovascular diseases."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Hypertension • Inflammation • Oncology • CAT • CCL2 • GDF15 • IL6 • TNFA

Epicardial vasospasm and concomitant ventricular tachycardia treated with Beta-1-specific Beta-blockade: a case series in support of nebivolol. (PubMed, Eur Heart J Case Rep) - "Selective beta-blockade may represent a therapeutic option in patients with high-risk epicardial spasm and ventricular arrhythmias. Furthermore, the apparent success of nebivolol in this setting suggests that hyperactive sympathetic input may represent a causal or aggravating factor in spasm-associated ventricular arrhythmias."

Journal • Cardiovascular • Ventricular Tachycardia

RaP-AF: Rate Control in Patients With Atrial Fibrillation (clinicaltrials.gov) - P=N/A | N=13 | Completed | Sponsor: National Taiwan University Hospital | Active, not recruiting ➔ Completed | N=50 ➔ 13

Enrollment change • Trial completion • Atrial Fibrillation • Cardiovascular

A Case of Post-Transplantation Lymphoproliferative Disorder Following Kidney Transplantation. (PubMed, Case Rep Nephrol) - "His regular medications included nebivolol 5 mg once a day, tacrolimus 4 mg twice a day, mycophenolate mofetil 500 mg twice a day, prednisolone 5 mg once a day, and insulin-novomix 14 units in the morning and 6 units at night. The tumor was subsequently excised. Histological specimen confirmed diffuse large B-cell lymphoma (DLBCL) as his final diagnosis."

Journal • B Cell Lymphoma • Cardiovascular • Constipation • Diabetes • Diffuse Large B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatitis C • Hypertension • Infectious Disease • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Oncology • Pain • Small Intestinal Carcinoma • Transplantation

Using Physiologically Based Pharmacokinetic Modeling and Simulations to Predict Antihypertensive Drug Doses in Cirrhotic Patients. (PubMed, J Clin Pharmacol) - "The model predicted that the healthy doses of nifedipine 20 mg three times daily (TID), verapamil 80 mg TID, nebivolol 10 mg once daily, and diltiazem 60 mg TID should be adjusted to 44%, 41%, 49.8%, and 51% of these doses, respectively, in the mild cirrhosis population. Among the studied drugs, nifedipine was the most affected and diltiazem was the least affected by cirrhosis, highlighting variability in hepatic impact across antihypertensive drugs. In the absence of dedicated clinical trials in cirrhosis for these drugs, validated PBPK models offer evidence-based insights to support clinicians in evaluating antihypertensive dosing options."

Journal • PK/PD data • Cardiovascular • Fibrosis • Gastroenterology • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis

Capillary blood microsampling and LC-Orbitrap analysis for adherence monitoring of cardiovascular drugs: method development, cross-validation, and patient proof-of-concept using VAMS and Capitainer-B. (PubMed, Talanta) - "Amlodipine, atenolol, atorvastatin, bisoprolol, carvedilol, clopidogrel, diltiazem, lercanidipine, metoprolol, nebivolol, prasugrel, rosuvastatin, salicylic acid, simvastatin hydroxy acid, and verapamil were included. In a proof-of-concept involving 30 patients, finger-prick concentrations from VAMS and Capitainer-B were interchangeable, supporting the suitability of these adherence workflows but reference ranges for capillary blood remain necessary to enable routine clinical interpretation. In summary, this work established a reliable, LC-Orbitrap-based microsampling platform for monitoring adherence and identified stability issued amongst others that guide future method selection and development."

Journal • Cardiovascular

Beyond the Heart: The Neuroprotective Potential of Nebivolol in Acute Myocardial Infarction. (PubMed, Life (Basel)) - "Both routes preserved cardiac function without affecting infarct size. These findings demonstrate that nebivolol, particularly via intravenous administration, provides significant NO-dependent neuroprotection during acute MI, supporting its potential as a dual-action therapeutic strategy targeting both cardiac and neurological complications."

Journal • Cardiovascular • Inflammation • Myocardial Infarction

Photochemical Deracemization of Chromanes and its Application to the Synthesis of Enantiopure Bioactive Compounds. (PubMed, Angew Chem Int Ed Engl) - "Reasonable pathways for back HAT were identified which are in line with deuterium labeling experiments. The method was applied to the concise preparation of five chromane-containing drugs (Doxazosin, Fidarestat, Nebivolol, Repinotan, Sarizotan) as single enantiomers."

Journal

Cardioprotection without risk? meta-analysis of prophylactic agents in low-risk cancer patients on anthracyclines (ASH 2025) - "We included randomized controlled trials (RCTs) of prophylactic ACE inhibitors, ARBs, beta-blockers, statins, dexrazoxane, or SGLT2 inhibitors in adults without pre-existing cardiovascular risk factors...Agents studied included beta-blockers (nebivolol, carvedilol, bisoprolol), ACE inhibitors (ramipril), ARBs (telmisartan), and spironolactone. Treatment duration ranged from 4 months to 1 year; anthracycline doses reached up to 689 mg/m² (epirubicin) or 536 mg/m² (doxorubicin)...The protective benefit was greater in contexts involving higher cumulative anthracycline doses and concurrent cardiotoxic therapies such as trastuzumab...However, high heterogeneity limits firm conclusions. Given the moderate effect size and heterogeneity, further large-scale, well-formulated trials are essential to identify optimal cardioprotective agents and precise patient selection criteria."

Retrospective data • Breast Cancer • Congestive Heart Failure • Heart Failure • Oncology • Solid Tumor

Diversified, endothelial cell-dependent cancer cell response to hypertensive serum modified by antihypertensive drugs. (PubMed, Sci Rep) - "Serum was collected from hypertensive patients treated with amlodipine, nebivolol, and perindopril for 6 weeks, alongside samples from healthy individuals. In summary, our study demonstrates that antihypertensive therapy, especially with nebivolol, potentially reverses hypertension-induced changes that exacerbate the cancer-promoting phenotype of endothelial cells. This suggests that beyond controlling blood pressure, antihypertensive treatments may also play a role in modulating cancer progression."

Journal • Cardiovascular • Hypertension • Oncology • Pulmonary Arterial Hypertension • ANGPT1 • CDH1 • CXCL1 • CXCL12 • CXCL8 • OCLN • TGFB1